Loading stock data…
$0.83-0.06 (-6.52%)
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Biofrontera Inc. in the Healthcare sector is trading at $0.83 with a market capitalization of $18M. Wall Street consensus targets $6.00 (2 analysts), implying a +619.2% move over the next 12 months. The stock is currently 50% below its 52-week high of $1.66, remaining 19.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 18 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.00M↑ | $10.08M↓ | $17.10M↑ | $6.99M↓ | $9.03M |
| Gross Profit | $9.59M↑ | $7.97M↓ | $14.09M↑ | $4.94M↓ | $6.39M |
| Operating Income | -$524,000↑ | -$3.93M↓ | $4.56M↑ | -$6.28M↓ | -$5.08M |
| Net Income | -$604,000↑ | -$4.75M↓ | $5.64M↑ | -$6.65M↓ | -$5.32M |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps...